Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14573044 | 0.80 | EPHX2 (0.53) | L3MBTL1EPHX2SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL9974906 | 0.78 | SMN1; SMN2 (0.45) | L3MBTL1EPHX2SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL1778693 | 0.78 | SMN1; SMN2 (0.61) | L3MBTL1EPHX2SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL17352418 | 0.77 | LMNA (0.55) | L3MBTL1EPHX2SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL18602790 | 0.77 | EPHX2 (0.35) | L3MBTL1EPHX2 | |
| SCHEMBL15022007 | 0.75 | EPHX2 (0.49) | L3MBTL1EPHX2SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL11150227 | 0.75 | L3MBTL1 (0.42) | L3MBTL1EPHX2CA1CA2 | |
| SCHEMBL13439144 | 0.75 | KCNH2 (0.37) | — | |
| SCHEMBL630318 | 0.74 | SMN1; SMN2 (0.42) | L3MBTL1EPHX2SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL17352352 | 0.73 | EPHX2 (0.58) | L3MBTL1EPHX2SMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3328826-B1 | NOVEL ADAMANTANE AND MEMANTINE DERIVATIVES AS PERIPHERAL NMDA RECEPTOR ANTAGONISTS | INST NAT SANTE RECH MED (FR) | 2020-02-26 | — | — | EP | disclosed |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2019-03-14 | — | — | US | disclosed |
| US-20180215699-A1 | NOVEL ADAMANTANE AND MEMANTINE DERIVATIVES AS PERIPHERAL NMDA RECEPTOR ANTAGONISTS | INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) (FR) | 2018-08-02 | — | — | US | disclosed |
| EP-3328826-A1 | NOVEL ADAMANTANE AND MEMANTINE DERIVATIVES AS PERIPHERAL NMDA RECEPTOR ANTAGONISTS | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017120194-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2017-07-13 | — | — | WO | disclosed |
| EP-2427425-B1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| WO-2017017116-A1 | NOVEL ADAMANTANE AND MEMANTINE DERIVATIVES AS PERIPHERAL NMDA RECEPTOR ANTAGONISTS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-02-02 | — | — | WO | disclosed |
| EP-2578212-B1 | COMPOUND INHIBITING ACTIVATION OF THE ENZYME ERK1/2 FOR USE IN THE TREATMENT OF NEUROGENERATIVE ILLNESSES | FARMALIDER SA (ES) | 2016-07-06 | — | — | EP | disclosed |
| US-6828318-B2 | Amines such as 2-(2-(2-phenyl)adamantyl)ethylamine, used as neurotransmitter antagonists, for prophylaxis of neurodegenerative disorders and as analgesics | VERNALIS RESEARCH LIMITED (GB) | 2004-12-07 | — | — | US | disclosed |
| US-6828318-B2 | Amines such as 2-(2-(2-phenyl)adamantyl)ethylamine, used as neurotransmitter antagonists, for prophylaxis of neurodegenerative disorders and as analgesics | VERNALIS RESEARCH LIMITED (GB) | 2004-12-07 | — | — | US | disclosed |
| EP-1305306-B1 | 2-ADAMANTYLETHYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RES LTD (GB) | 2004-11-24 | — | — | EP | disclosed |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-10-28 | — | — | US | disclosed |
| US-20030207881-A1 | 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission | VERNALIS RESEARCH LIMITED (GB) | 2003-11-06 | — | — | US | disclosed |
| US-20030207881-A1 | 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission | VERNALIS RESEARCH LIMITED (GB) | 2003-11-06 | — | — | US | disclosed |
| EP-1305306-A2 | 2-ADAMANTYLETHYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002008219-A2 | 2-ADAMANTYLETHYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2002-01-31 | — | — | WO | disclosed |
| EP-0584220-A1 | ENGINEERING THE LOCAL INFLAMMATORY RESPONSE AS A MEANS OF CONTROLLED RELEASE DRUG DELIVERY | ENDOCON, INC. (US) | 1994-03-02 | — | — | EP | disclosed |
| WO-1992020325-A1 | ENGINEERING THE LOCAL INFLAMMATORY RESPONSE AS A MEANS OF CONTROLLED RELEASE DRUG DELIVERY | ENDOCON, INC. (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215699-A1 | NOVEL ADAMANTANE AND MEMANTINE DERIVATIVES AS PERIPHERAL NMDA RECEPTOR ANTAGONISTS | GRIN1, GRIN2A, GRIN2B | L3MBTL1 4747/4885EPHX2 3207/4885SMN1; SMN2 1965/4885 |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | L3MBTL1 3865/4885EPHX2 1309/4885SMN1; SMN2 3678/4885 |
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | L3MBTL1 4736/4885EPHX2 4690/4885SMN1; SMN2 3203/4885 |
| US-20030207881-A1 | 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission | SLC1A2, SLC18A2, GRM2 | L3MBTL1 1652/4885EPHX2 784/4885SMN1; SMN2 996/4885 |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | L3MBTL1 4736/4885EPHX2 4690/4885SMN1; SMN2 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.